References
- Fauci AS, Morens DM. The perpetual challenge of infectious diseases. N. Engl. J. Med. 366(5), 454–461 (2012).
- de Martel C, Ferlay J, Franceschi S et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 13(6), 607–615 (2012).
- Russell W. An address on a characteristic organism of cancer. Br. Med. J. 2(1563), 1356–1360 (1890).
- Weiss RA, Vogt PK. 100 years of Rous sarcoma virus. J. Exp. Med. 208(12), 2351–2355 (2011).
- Epstein MA, Achong BG, Barr YM. Virus particles in cultured lymphoblasts from Burkitt’s lymphoma. The Lancet 1, 702–703 (1964).
- IARC. Monographs on the evaluation of carcinogenic risks to humans. Vol. 61, schistosomes, liver flukes and Helicobacter pylori. IARC, Lyon, France (1994).
- IARC. Monographs on the evaluation of carcinogenic risks to humans. Vol. 59, hepatitis viruses. IARC, Lyon, France (1994).
- IARC. Monographs on the Evaluation of carcinogenic risks to humans. Vol. 67, human immunodeficiency viruses and human t-cell lymphotropic viruses. IARC, Lyon, France (1996).
- IARC. Monographs on the Evaluation of Carcinogenic Risks to Humans: vol. 70, Infections With Epstein–Barr Virus and Human Herpes Viruses. IARC, Lyon, France (1997).
- IARC. Monographs on the evaluation of carcinogenic risks to humans. Vol. 90, human papillomaviruses. IARC, Lyon, France (2005).
- Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int. J. Cancer 118(12), 3030–3044 (2006).
- Yosry A. Schistosomiasis and neoplasia. Contrib. Microbiol. 13, 81–100 (2006).
- Hatakeyama M, Higashi H. Helicobacter pylori CagA: a new paradigm for bacterial carcinogenesis. Cancer Sci. 96(12), 835–843 (2005).
- Mager DL. Bacteria and cancer: cause, coincidence or cure? A review. J. Transl. Med. 4, 14 (2006).
- Cheung TK, Xia HH, Wong BC. Helicobacter pylori eradication for gastric cancer prevention. J. Gastroenterol. 42(Suppl. 17), 10–15 (2007).
- Stanley MA. Genital human papillomavirus infections: current and prospective therapies. J. Gen. Virol. 93(Pt 4), 681–691 (2012).
- Labro MT. Immunomodulatory effects of antimicrobial agents. Part I: antibacterial and antiviral agents. Expert Rev. Anti. Infect. Ther. 10(3), 319–340 (2012).
- Labro MT. Immunomodulatory effects of antimicrobial agents. Part II: antiparasitic and antifungal agents. Expert Rev. Anti. Infect. Ther. 10(3), 341–357 (2012).
- Peeters TL. Agonist effect of erythromycin and its analogues on motilin receptors. A new family of prokinetics? Clinical interest. Acta Gastroenterol. Belg. 56(3–4), 257–260 (1993).
- Moncet D, Morando DJ, Pitoia F, Katz SB, Rossi MA, Bruno OD. Ketoconazole therapy: an efficacious alternative to achieve eucortisolism in patients with Cushing’s syndrome. Medicina (B. Aires) 67(1), 26–31 (2007).
- Millikan R, Baez L, Banerjee T et al. Randomized Phase 2 trial of ketoconazole and ketoconazole/doxorubicin in androgen independent prostate cancer. Urol. Oncol. 6(3), 111–115 (2001).
- Patz EF Jr, McAdams HP, Erasmus JJ et al. Sclerotherapy for malignant pleural effusions: a prospective randomized trial of bleomycin vs doxycycline with small-bore catheter drainage. Chest 113(5), 1305–1311 (1998).
Websites
- WHO – the global burden of disease. 2004 update. www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf
- WHO – antimicrobial resistance. www.who.int/mediacentre/factsheets/fs194/en
- WHO – cancer. www.who.int/mediacentre/factsheets/fs297/en